Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-11-02
DOI
10.1007/s00259-021-05594-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET
- (2021) Elisabeth Pfaehler et al. EJNMMI Research
- Current and emerging clinical applications of PSMA-PET diagnostic imaging for prostate cancer
- (2021) Andrea Farolfi et al. JOURNAL OF NUCLEAR MEDICINE
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- AI-based detection of lung lesions in [18F]FDG PET-CT from lung cancer patients
- (2021) Pablo Borrelli et al. EJNMMI Physics
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival
- (2021) Jens Kurth et al. NUCLEAR MEDICINE COMMUNICATIONS
- Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT
- (2021) Fadi Khreish et al. Cancers
- Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy
- (2021) Fadi Khreish et al. Biomolecules
- New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
- (2020) Florian Rosar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
- (2020) Justin Ferdinandus et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
- (2020) Hojjat Ahmadzadehfar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks
- (2020) Skander Jemaa et al. JOURNAL OF DIGITAL IMAGING
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Value of Baseline and Interim Total Metabolic Tumour Volume and Total Lesion Glycolysis Measured on 18F-FDG PET/CT in Patients with Follicular Lymphoma
- (2019) Jin-Hua Liang et al. Cancer Research and Treatment
- Clinical outcomes of 177Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy naïve patients with metastatic castration resistant prostate cancer
- (2019) Thomas W Barber et al. JOURNAL OF NUCLEAR MEDICINE
- Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma
- (2019) Domenico Albano et al. ANNALS OF NUCLEAR MEDICINE
- 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer
- (2019) Wojciech Cytawa et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates
- (2019) MaryBeth B. Culp et al. EUROPEAN UROLOGY
- Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art
- (2019) Raquel Perez-Lopez et al. RADIOLOGY
- 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
- (2019) Fadi Khreish et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy
- (2019) Kerstin Michalski et al. NUKLEARMEDIZIN-NUCLEAR MEDICINE
- The value of tumor markers in men with metastatic prostate cancer undergoing [ 177 Lu]Lu‐PSMA therapy
- (2019) Anna Yordanova et al. PROSTATE
- Proposal of Systemic Therapy Response Assessment Criteria in time of PSMA PET/CT imaging: PSMA PET Progression (PPP)
- (2019) Stefano Fanti et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer
- (2018) Christian Schmidkonz et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
- (2018) Bernhard Grubmüller et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
- (2017) Axel Bräuer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
- (2017) Wolfgang P. Fendler et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PSMA Ligands for PET Imaging of Prostate Cancer
- (2017) Sarah M. Schwarzenboeck et al. JOURNAL OF NUCLEAR MEDICINE
- 177 Lu-PSMA Radioligand Therapy for Prostate Cancer
- (2017) Wolfgang P. Fendler et al. JOURNAL OF NUCLEAR MEDICINE
- Initial Experience with Volumetric68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer
- (2017) Sebastian Schmuck et al. JOURNAL OF NUCLEAR MEDICINE
- Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered
- (2017) Ellen S. de Morrée et al. JAMA Oncology
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status
- (2015) Arun A. Azad et al. EUROPEAN UROLOGY
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- (2014) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterising the castration-resistant prostate cancer population: a systematic review
- (2011) M. Kirby et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now